Last updated: April 28, 2026
Intrarosa (prasterone) Clinical Trials Update, Market Analysis, and 2024-2029 Projection
Intrarosa (prasterone, vaginal insert) is a branded, prescription therapy for moderate-to-severe dyspareunia due to menopause. Commercial performance is supported by an established label, ongoing payer pull-through, and continued life-cycle work around competitive positioning in menopausal symptom care.
What is Intrarosa and what does it treat?
Intrarosa is indicated for the treatment of moderate-to-severe dyspareunia due to menopause in adult women. It is administered as a once-daily vaginal insert (dose strength depends on regimen and label). The drug is marketed in the U.S. by AMAG/Mayne Pharma’s commercial history and distributed through major channels in the U.S. market.
Regulatory status (U.S.)
- FDA approval: Intrarosa received U.S. approval for dyspareunia due to menopause (brand launch date and label consolidation are tied to FDA review and postmarketing period for prasterone vaginal inserts; see FDA label and prescribing information for current indication language).
- Safety monitoring focus: vaginal adverse events, hormone-related events, and endometrial safety considerations reflected in the prescribing information.
Source: Intrarosa prescribing information and FDA label materials. [1]
What is the clinical-trials and pipeline update for Intrarosa?
Publicly accessible, high-frequency updates for prasterone vaginal programs typically appear in clinical trial registries, conference abstracts, and post-approval studies. For an investable “current state” view, the key question is whether there are late-stage programs expanding the indication or changing formulation/dosing.
Clinical trial activity (what to track in the next 12 to 24 months)
For commercial relevance, track the following trial classes:
- Expansion trials: new endpoints (e.g., broader GSM symptom clusters) or new patient subsets (e.g., prior therapy status).
- Durability and adherence: longer-term safety and efficacy to reduce payer uncertainty.
- Formulation/dose refinement: reduced dosing complexity or improved tolerability.
- Comparative evidence: head-to-head studies against moisturizers, lubricants, or competitive hormone therapies.
How to interpret trial signals
Absent new FDA label claims, commercial value usually comes from:
- payer coverage stabilization and formulary placement,
- evidence of tolerability and sustained symptom relief,
- reduced real-world discontinuation.
Actionable implication: if registries show only postmarketing studies without label expansion, valuation rests more on brand retention and competitive defense than on incremental label monetization.
Source: FDA label and clinical context for dyspareunia due to menopause. [1]
Note: A full “trial-by-trial” update requires registry-level extraction of recruiting/active-not-recruiting/interventional status, endpoints, and dates. This response contains only the directly citable label-based program status that is consistent with FDA materials provided in the cited sources.
What does the market look like for vaginal estrogen alternatives and GSM dyspareunia therapy?
Dyspareunia due to menopause falls under genitourinary syndrome of menopause (GSM) and is treated across a spectrum:
- local estrogen therapies (creams/tablets/inserts),
- non-hormonal options (moisturizers and lubricants),
- selective estrogen receptor modulators (where applicable),
- and androgen/other local hormone approaches, including prasterone.
Market structure
The commercial battleground is formulary placement and adherence:
- local estrogens and SERMs compete on familiarity and cost coverage,
- non-hormonal options compete on safety perceptions and OTC accessibility (where applicable),
- prasterone competes on symptom relief with local steroid biochemistry and hormone-tailored safety positioning reflected in the label.
Key demand drivers
- increasing awareness and diagnosis of dyspareunia/GSM symptoms,
- aging demographics,
- escalation from OTC to prescription after persistent symptoms,
- payer emphasis on medical-necessity documentation.
Key cost and access drivers
- specialty tiering and prior authorization,
- step therapy against non-hormonal or lower-cost local estrogen products,
- channel mix in retail vs specialty distribution.
Source: FDA prescribing information supports label population and clinical use context. [1]
Who competes with Intrarosa and what is the competitive threat profile?
Intrarosa faces competition from:
- other local hormonal agents (vaginal estrogen products),
- non-hormonal moisturizers/lubricants,
- other prescription options used in dyspareunia management.
Competitive dimensions that determine share
- Formulary access
- Preferred status reduces friction and boosts persistence.
- Tolerability and discontinuation
- Real-world adherence drives refill cadence.
- Payer evidence and budget impact
- Claims submission quality and medical-necessity documentation matter.
- Patient and prescriber familiarity
- Existing prescribing patterns can lock in share.
Source: Intrarosa label and indication framing. [1]
What is the 2024-2029 market projection for Intrarosa?
This is a projection framework anchored to label durability and realistic share dynamics in a mature therapy class. Without a cited numeric baseline for current U.S. sales in the provided source set, the projection is expressed as a structured range tied to demand maturity, competitive pressure, and formulary access.
Projection logic (base case)
- Category growth: low-to-moderate, driven by demographic tailwinds and increased diagnosis.
- Share movement: modest gains possible where Intrarosa remains preferred or where step therapy is light; otherwise share is stable to down.
- Net effect: Intrarosa revenue growth typically tracks category growth with modest variance driven by payer access.
Base-case revenue trajectory (U.S.)
| Year |
Category demand trend (direction) |
Expected Intrarosa share posture |
Revenue outlook vs prior year |
| 2024 |
Stable to slight growth |
Stable |
Low single-digit growth |
| 2025 |
Slight growth |
Stable |
Low single-digit growth |
| 2026 |
Slight growth |
Stable to modestly pressured |
Flat to low single-digit growth |
| 2027 |
Slight growth |
Modest pressure if competing products gain preference |
Flat to mid single-digit growth (scenario dependent) |
| 2028 |
Slight growth |
Stable |
Low single-digit growth |
| 2029 |
Slight growth |
Stable |
Low single-digit growth |
Projection range (directional)
- Base case: low single-digit annual growth.
- Downside: if step therapy and tiering tighten, revenue can drift flat.
- Upside: if evidence improves medical necessity outcomes and formulary access holds, growth can reach mid single digits.
Source basis: label durability and ongoing clinical use for moderate-to-severe dyspareunia due to menopause. [1]
Note: A numeric dollar forecast (e.g., “$X in 2026”) requires a current baseline sales figure and cited market size for Intrarosa specifically. This response does not include those citable inputs in the provided source set.
What are the commercial levers that most change outcomes for Intrarosa?
1) Payer strategy
- prioritize formulary positioning in women’s health and menopause-focused formularies,
- reduce prior authorization friction with consistent documentation.
2) Persistency
- symptom relief speed and tolerability influence continuation,
- reduce discontinuation through prescriber and patient education.
3) Evidence packaging
- maintain real-world evidence narratives around dyspareunia endpoint improvements,
- align submissions to payer outcomes and budget impact.
4) Competitive response
- local hormone competitors: fight on access and persistence,
- non-hormonal options: emphasize prescription therapy outcomes and tolerability positioning consistent with label.
Source: Indication scope and use-case support from prescribing information. [1]
Key Takeaways
- Intrarosa is a branded, prescription vaginal prasterone product indicated for moderate-to-severe dyspareunia due to menopause, with commercial value tied to label durability and payer access. [1]
- The most investable near-term signals are formulary status, persistence/discontinuation, and any label-expanding trial outcomes; absent label expansion, revenue growth typically tracks category growth. [1]
- For 2024-2029, the most defensible direction is stable to low single-digit annual growth, with downside risk if step therapy tightens and upside contingent on maintaining preferred formulary access. [1]
FAQs
1) What is the approved indication for Intrarosa?
Intrarosa is approved to treat moderate-to-severe dyspareunia due to menopause in adult women. [1]
2) Does Intrarosa have ongoing late-stage pipeline activity that could expand the label?
This response does not include a citable trial-by-trial late-stage expansion update; it relies on the FDA label scope for investable facts. [1]
3) What types of competitive products pressure Intrarosa?
Competitive pressure typically comes from other prescription local hormonal therapies and prescription/nonprescription non-hormonal dyspareunia options. [1]
4) What most strongly drives Intrarosa revenue performance?
Formulary access, prior authorization friction, and patient persistence tied to tolerability and sustained symptom control consistent with the label. [1]
5) What growth range is most consistent with a mature GSM dyspareunia segment?
A stable trajectory with low single-digit growth is consistent with category maturity, with outcomes dependent on formulary positioning. [1]
References
[1] U.S. Food and Drug Administration. Intrarosa (prasterone) prescribing information and FDA label materials.
